Gain Therapeutics, Inc. (Nasdaq: GANX) has announced the completion of target enrollment in its Phase 1b clinical study evaluating GT-02287 in individuals with Parkinson's Disease, with or without a GBA1 mutation. As of June 30, 2025, the study reached 16 participants, surpassing its initial goal. The independent data monitoring committee has recommended continuing the study without changes, as no serious treatment emergent adverse events have been reported. Biomarker analysis from cerebrospinal fluid samples is now expected in the fourth quarter of 2025, earlier than initially planned. Gain Therapeutics is extending the screening window for additional participants through July 31, 2025, and is considering extending the dosing period beyond the current 90-day protocol. Results of the biomarker analysis will be presented in the future, during the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.